Most Recent
The Full Federal Court has upheld a decision revoking Otsuka Pharmaceuticals’ patent extension for an injectable version of antipsychotic drug Abilify, finding the patent expired last year.
Samsung Bioepis has successfully opposed Janssen's bid to patent a monoclonal antibody to treat ulcerative colitis, but an IP Australia delegate has given the J&J-owned company a chance to fix its application.
Abbey Animal Health has appealed its loss in a suit seeking to invalidate rival Virbac's patent for an antiparasitic drug.
Abbey Animal Health has managed only a “pyrrhic victory" in a patent case against rival Virbac over an antiparasitic drug, and must withdraw its Levamox Duo product from the market, a court has found.
Explosives company Dyno Nobel is appealing a court's dismissal of its case seeking to invalidate patents owned by rival Orica for a wireless detonation device.
Otsuka Pharmaceuticals is challenging a decision revoking its patent for an injectable version of antipsychotic drug Abilify.
A judge has refused to stay a fight between the tax office and software company Oracle over royalties, finding determination of the dispute will guide 15 other cases.
Samsung Bioepis can't get indemnity costs from Janssen Biotech after it surrendered patents for Crohn’s disease drug Stelara and filed a fresh case based on new patents for the drug.
A judge has issued a self-executing order for the dismissal of a patent infringement lawsuit against Monster Energy if the inventor who brought the case fails to pay $350,000 in security for the beverage giant's costs within two weeks.
The security sum sought by Monster Energy from an inventor suing the beverage giant for patent infringement was "manifestly excessive", a judge has said, and was based on an estimate of costs that included the fees of three solicitors and two barristers at an interlocutory hearing.